News from AAOS: Bacterin Launches New Orthopedic Allograft

During this year’s American Academy of Orthopaedic Surgeons annual meeting in New Orleans, La. (March 11-15), Bacterin International Holdings Inc. launched its OsteoSTX, a new allograft for orthopedic procedures. Using Bacterin’s proprietary demineralization technology, OsteoSTX are flexible cortical demineralized bone matrix matchsticks designed for multli-level and deformity spinal applications.

“This is the first product Bacterin has launched since I joined the company, and I have been very pleased with the process and the results,” said Dan Goldberger, Bacterin president and CEO. “We introduced this product to key opinion leaders at the NASS Evidence and Technology Spine Summit and the feedback was astounding. I am looking forward to seeing how distribution of this new product will help support our growth goals, and complement our existing product portfolio.”

OsteoSTX is the first product in Bacterin’s biologic portfolio designed specifically for addressing multi-level spine procedures and deformity cases. Bacterin officials claim the company is the first to market a product of this type for single-use application. OsteoSTX has already been implanted in patients, resulting in “strong surgeon feedback,” company officials noted.

Belgrade, Mont.-based Bacterin manufactures biologics products for domestic and international markets. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin’s Medical Device division develops coatings for various medical device applications.